10-Q: GT Biopharma Narrows Q3 Loss, Boosts Equity, Advances Pipeline

GT Biopharma reported a significantly reduced net loss and a return to positive stockholders' equity for the nine months ended September 30, 2025, while advancing its TriKE immuno-oncology pipeline.

Summary

• Net loss for the nine months ended September 30, 2025, significantly decreased to $5.3 million from $9.4 million in the prior year period.
• The company achieved positive stockholders' equity of $3.0 million as of September 30, 2025, a substantial improvement from a deficit of $(1.67) million at December 31, 2024.
• Working capital improved significantly to $3.0 million from a deficit of $(1.67) million.
• Research and development expenses decreased by 46% to $2.1 million for the nine months ended September 30, 2025, compared to $3.9 million in the prior year.
• Selling, general, and administrative expenses decreased by 33% to $4.7 million for the nine months ended September 30, 2025, from $6.7 million in the prior year, primarily due to reduced legal fees.
• GT Biopharma regained compliance with Nasdaq's Minimum Stockholders Equity Requirement on June 13, 2025.
• Clinical study enrollment for GTB-3650, a next-generation TriKE for AML and high-risk MDS, began on January 21, 2025, following FDA IND clearance in late June 2024.
• IND submission for GTB-5550, a B7-H3 targeted TriKE for advanced solid tumors, is anticipated in late December 2025 or January 2026.
• The company raised $7.47 million in net cash from financing activities for the nine months ended September 30, 2025, including proceeds from Series L convertible preferred stock and warrant exercises.
• A legal services firm reduced the company's prior year unpaid fees by approximately $1 million, recognized as other income in March 2025.

Sentiment

Score: 6

Explanation: The sentiment is cautiously positive. Significant financial improvements, including a reduced net loss, positive stockholders' equity, and regaining NASDAQ compliance, are strong positives. Pipeline progress with GTB-3650 clinical enrollment and anticipated GTB-5550 IND submission also contribute positively. However, the persistent 'going concern' warning and multiple ongoing legal disputes introduce substantial uncertainty and temper overall optimism.

Positives

• Net loss decreased by 43% to $5.3 million for the nine months ended September 30, 2025, compared to $9.4 million in the prior year.
• Stockholders' equity turned positive to $3.0 million as of September 30, 2025, from a deficit of $(1.67) million at December 31, 2024.
• Working capital improved by $4.67 million, moving from a deficit to a positive balance of $3.0 million.
• Regained compliance with Nasdaq's Minimum Stockholders Equity Requirement on June 13, 2025.
• Research and development expenses decreased by $1.8 million (46%) for the nine months ended September 30, 2025, due to lower production and material costs.
• Selling, general, and administrative expenses decreased by $2.2 million (33%) for the nine months ended September 30, 2025, driven by significant reductions in legal fees.
• GTB-3650 clinical study enrollment commenced on January 21, 2025, following FDA IND clearance.
• Anticipated IND submission for GTB-5550 in late December 2025 or January 2026, indicating pipeline progression.
• Successful capital raising activities, including a $20 million committed equity facility and $5.44 million net proceeds from Series L preferred stock and warrants issuance.

Negatives

• The company continues to sustain operating losses, with a net loss of $5.3 million for the nine months ended September 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern within one year, as stated by management and independent auditors.
• Cash and cash equivalents decreased to $2.53 million as of September 30, 2025, from $3.95 million at December 31, 2024.
• Net cash used in operating activities was $8.89 million for the nine months ended September 30, 2025.
• Multiple ongoing legal proceedings, including disputes with a former CFO and claims related to convertible notes, could result in significant liabilities and divert management attention.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to sustained operating losses and insufficient cash resources to fund anticipated operations for the next year.
• Inability to secure additional financing on acceptable terms, which could force delays, reductions, or elimination of discretionary spending and adversely affect business prospects.
• Potential delisting from Nasdaq if the company fails to maintain compliance with listing rules, which could negatively impact capital raising and stock liquidity.
• Adverse outcomes from ongoing legal proceedings (Ohri, TWF Global, Silberfein/DiPietro/Werthman Trust matters) could result in significant financial losses or other demands.
• Reliance on third-party agreements for research, development, and manufacturing services (e.g., Cytovance Biologics, University of Minnesota), posing risks if these relationships are disrupted or terms change.
• Risks associated with clinical development, including the potential for delays, unfavorable results, or failure to obtain regulatory approvals for product candidates like GTB-3650 and GTB-5550.
• Dilution of common stockholders' equity due to ongoing and future equity financings, including the exercise of warrants and conversion of preferred stock.

Future Outlook

The company anticipates submitting an Investigational New Drug (IND) application for GTB-5550 in late December 2025 or January 2026. Clinical study enrollment for GTB-3650 is ongoing, with data collection throughout the year. The company is also exploring and assessing potential manufacturers for GTB-7550. Future liquidity depends on securing additional financing, without which operations may be delayed, reduced, or eliminated.

Management Comments

• Management believes the TriKE and Dual Targeting TriKE platforms, which activate endogenous NK cells, are potentially safer than T-cell immunotherapy due to less cytokine release syndrome and fewer neurological complications.
• Management believes the preclinical data suggests that the TriKE dependent CD16 directed IL-15 proliferation of NK cells has little effect on endogenous T cells, explaining the safety profile.
• Management's goal is to be a leader in immuno-oncology therapies targeting a broad range of indications, including hematological malignancies and solid tumors, by introducing a next-generation camelid nanobody platform.
• Management believes the claims related to the ongoing legal proceedings are without merit and intends to vigorously defend against them.

Industry Context

GT Biopharma operates in the highly competitive immuno-oncology sector, focusing on novel Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. These platforms aim to harness natural killer (NK) cells for cancer treatment, a growing area of interest in immunotherapy. The shift to camelid nanobody technology for second-generation TriKEs like GTB-3650 and GTB-5550 reflects an industry trend towards developing more potent and stable antibody-derived therapeutics. The company's pipeline addresses significant unmet needs in hematologic malignancies (AML, MDS), solid tumors, and potentially autoimmune disorders (lupus), positioning it within a broad and evolving therapeutic landscape. The ongoing collaborations with institutions like the University of Minnesota are common in early-stage biopharma for leveraging academic research and expertise.

Comparison to Industry Standards

• NA The filing does not provide specific comparable companies, projects, or results for direct industry comparison.

Management Changes

Corporate Governance

Legal Proceedings

• Ohri Matter: AAA Arbitration Demand filed on July 22, 2024, against former CFO Manu Ohri for breach of fiduciary duties and contract. Mr. Ohri filed counterclaims. The final hearing is postponed indefinitely for mediation, with a status conference scheduled for December 11, 2025.
• TWF Global Matter: Z-One, LLC filed a new Complaint on February 17, 2025, alleging breach of a convertible note with a principal amount of $150,000 and seeking damages exceeding $500,000. The company filed a motion to dismiss on August 26, 2025.
• Silberfein, DiPietro, and Werthman Trust Matters: Three separate lawsuits filed on July 8-9, 2025, alleging breach of securities purchase agreements and convertible notes (principal amounts of $100,000 or $150,000 each) and seeking damages exceeding $500,000 each. The company intends to seek dismissal of these complaints.

Related Party Transactions

• Cytovance Biologics, Inc.: Accounts payable to Cytovance, a related party (owns >5% common stock), decreased from $1,183,000 to $60,000. The company issued pre-funded warrants valued at $847,000 in March 2025 and common stock valued at $810,000 in 2024 to settle payables. Commitments for unbilled SOWs amount to approximately $273,000.
• University of Minnesota: The 2023 Sponsored Research Agreement was amended to expire on December 31, 2025, with additional payments of $216,000. The 2016 Exclusive Patent License Agreement was amended on May 13, 2024, requiring an upfront payment of $145,000 and revised maintenance/royalty fees. The 2024 GTB-3650 Clinical Trial Agreement has a budget of approximately $2.1 million over three years, with commitments of approximately $1.9 million unbilled as of September 30, 2025.
• PDPC Advisors Inc.: Entered into an Advisory Agreement on June 30, 2025, for $100,000 in cash payments and a pre-funded warrant to purchase 150,000 shares of common stock with a fair value of $537,000. PDPC is considered a related party due to its CEO's beneficial ownership.

Stakeholder Impact

• Shareholders: Experienced dilution from recent equity offerings and warrant exercises, but benefited from the company regaining Nasdaq compliance and the reclassification of preferred stock to equity, which improved the balance sheet. Future share price could be influenced by clinical trial results and ongoing legal proceedings.
• Employees and Management: Received new stock option awards, providing incentive and aligning interests with company performance.
• Customers (future patients): Potential benefit from the advancement of TriKE product candidates (GTB-3650, GTB-5550, GTB-7550) into clinical trials and development for various cancers and autoimmune disorders.
• Suppliers and Creditors: Accounts payable to key vendors like Cytovance Biologics and the University of Minnesota are being managed, including through equity settlements. A legal services firm reduced prior year unpaid fees by $1 million, benefiting the company's financial position.
• Regulatory Bodies (FDA, Nasdaq): The company is actively engaging with the FDA for IND applications and has regained compliance with Nasdaq listing rules, demonstrating adherence to regulatory requirements.

Next Steps

• Continue clinical study enrollment and data collection for GTB-3650.
• Anticipate submission of an IND application for GTB-5550 in late December 2025 or January 2026.
• Explore and assess potential manufacturers for GTB-7550.
• Attend a status conference for the Ohri arbitration matter on December 11, 2025.
• Continue to vigorously defend against legal claims in the TWF Global and Silberfein/DiPietro/Werthman Trust matters.
• Nasdaq will continue to monitor the company's compliance with the Minimum Stockholders Equity Requirement.

Key Dates

Recommendation

While GT Biopharma has shown significant financial improvements, including a reduced net loss, a shift to positive stockholders' equity, and regaining Nasdaq compliance, the 'going concern' warning remains a critical concern. The progress in the TriKE pipeline with GTB-3650 entering clinical trials and GTB-5550's IND submission on the horizon is positive, but these are early-stage developments with inherent high risks. The company's ability to secure future financing is paramount. Additionally, multiple ongoing legal proceedings introduce uncertainty and potential liabilities. For a seasoned investor, the current situation presents a mixed bag of improving financials and pipeline potential against significant operational and legal risks, warranting a 'hold' position to monitor further developments, particularly regarding sustained liquidity and clinical trial outcomes.

Keywords

Biopharma, Immuno-oncology, TriKE, NK cells, AML, MDS, Solid Tumors, Clinical Stage, NASDAQ, SEC Filing, GTBP, GT Biopharma, Preferred Stock, Warrants, Going Concern